CONFLICT OF INTEREST DISCLOSURES
N.L.H. receives research funding from Lilly Pharmaceuticals and
AstraZeneca. D.F.H. receives research funding from Astra-
Zeneca, Novartis, Pfizer, and Veridex, and has an immediate fam-
ily member who is employed by Lilly. C.V.P. receives research
funding from Novartis and Amgen. J.B.S. received honoraria
from Lilly Pharmaceuticals until July 2008. M.W. is a consultant
for Pfizer. M.B., A.F.S., and J.J.G. have no disclosures.
1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American
Society of Clinical Oncology clinical practice guideline:
update on adjuvant endocrine therapy for women with hor-
mone receptor-positive breast cancer. J Clin Oncol. 2010;28:
2. Winer EP, Hudis C, Burstein HJ, et al. American Society
of Clinical Oncology technology assessment on the use of
aromatase inhibitors as adjuvant therapy for postmenopausal
women with hormone receptor-positive breast cancer: status
report 2004. J Clin Oncol. 2005;23:619-629.
3. Henry NL, Giles JT, Ang D, et al. Prospective characteriza-
tion of musculoskeletal symptoms in early stage breast can-
cer patients treated with aromatase inhibitors. Breast Cancer
Res Treat. 2008;111:365-372.
4. Henry NL, Giles JT, Stearns V. Aromatase inhibitor-associ-
ated musculoskeletal symptoms: etiology and strategies for
management. Oncology. 2008;22:1401-1408.
5. Lintermans A, Van Calster B, Van Hoydonck M, et al. Aro-
matase inhibitor-induced loss of grip strength is body mass
index dependent: hypothesis-generating findings for its
pathogenesis. Ann Oncol. [published online ahead of print
January 27, 2011.]
6. Crew KD, Greenlee H, Capodice J, et al. Prevalence of
joint symptoms in postmenopausal women taking aromatase
inhibitors for early-stage breast cancer. J Clin Oncol. 2007;
7. Crew KD, Capodice J, Greenlee H, et al. Randomized,
blinded, sham-controlled trial of acupuncture for the man-
agement of aromatase inhibitor-associated joint symptoms in
women with early-stage breast cancer. J Clin Oncol. 2010;
8. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C,
Demitrack MA. Duloxetine in the treatment of depression:
a double-blind placebo-controlled comparison with paroxe-
tine. J Clin Psychopharmacol. 2004;24:389-399.
9. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine,
a centrally acting analgesic, in the treatment of patients with
osteoarthritis knee pain: A 13-week, randomized, placebo-
controlled trial. Pain. 2009;146:253-260.
10. Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ.
Duloxetine for the management of diabetic peripheral neu-
ropathic pain: response profile. Pain Med. 2007;8:397-409.
11. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and
safety of duloxetine in patients with chronic low back pain.
12. Arnold LM, Pritchett YL, D’Souza DN, Kajdasz DK, Iyengar
S, Wernicke JF. Duloxetine for the treatment of fibromyalgia
in women: pooled results from 2 randomized, placebo-
controlled clinical trials. J Womens Health. 2007;16:1145-1156.
13. Joffe H, Soares CN, Petrillo LF, et al. Treatment of depres-
sion and menopause-related symptoms with the serotonin-
norepinephrine reuptake inhibitor duloxetine. J Clin Psychia-
14. Chalon S, Pereira A, Lainey E, et al. Comparative effects of
duloxetine and desipramine on sleep EEG in healthy sub-
jects. Psychopharmacology. 2005;177:357-365.
15. Daut RL, Cleeland CS, Flanery RC. Development of the
Wisconsin Brief Pain Questionnaire to assess pain in cancer
and other diseases. Pain. 1983;17:197-210.
16. Bruce B, Fries JF. The Stanford Health Assessment Ques-
tionnaire: a review of its history, issues, progress, and docu-
mentation. J Rheumatol. 2003;30:167-178.
17. Carpenter JS, Andrykowski MA, Wilson J, et al. Psychometrics
for 2 short forms of the Center for Epidemiologic Studies-
Depression Scale. Issues Ment Health Nurs. 1998;19:481-494.
18. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific
quality of life questionnaire: development and psychometric
properties. Maturitas. 1996;24:161-175.
19. Carpenter JS. The Hot Flash Related Daily Interference
Scale: a tool for assessing the impact of hot flashes on qual-
ity of life following breast cancer.
J Pain Symptom Manage.
20. Buysse DJ, Reynolds CF III, Monk TH, Hoch CC, Yeager
AL, Kupfer DJ. Quantification of subjective sleep quality in
healthy elderly men and women using the Pittsburgh Sleep
Quality Index (PSQI). Sleep. 1991;14:331-338.
21. Carpenter JS, Andrykowski MA. Psychometric evaluation of the
Pittsburgh Sleep Quality Index. J Psychosom Res. 1998;45:5-13.
22. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting
the clinical importance of treatment outcomes in chronic
pain clinical trials: IMMPACT recommendations. J Pain.
23. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich
MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-
daily in the treatment of painful physical symptoms in
patients with major depressive disorder. J Psychiatr Res.
24. Tittle MB, McMillan SC, Hagan S. Validating the brief
pain inventory for use with surgical patients with cancer.
Oncol Nurs Forum. 2003;30:325-330.
25. Grimm SW, Dyroff MC. Inhibition of human drug metabo-
lizing cytochromes P450 by anastrozole, a potent and selective
inhibitor of aromatase. Drug Metab Dispo s. 1997;25:598-602.
26. Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized,
double-blind, placebo-controlled evaluation of pregabalin for
alleviating hot flashes, N07C1. JClinOncol. 2010;28:641-647.
Duloxetine for AI-Associated Arthralgias/Henry et al
Cancer December 15, 2011 5475